Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Glenn J HannaHarita DharanesswaranAnita Giobbie-HurderJohn J HarranZixi LiaoLori PaiVatche TchekmedyianEmily S RuizAbigail H WaldmanChrysalyne D SchmultsLeonardo V RiellaPatrick H LizotteCloud P PaweletzAnil K ChandrakerNaoka MurakamiAnn W SilkPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
mTOR inhibitor and corticosteroids represent a favorable immunosuppressive regimen for KTRs with advanced CSCC receiving immunotherapy. This combination resulted in durable antitumor responses with no kidney rejection events (funded by Regeneron Pharmaceuticals; ClinicalTrials.gov identifier: NCT04339062).